Chimeric protein for prevention and treatment of HIV infection
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsEdward A. Berger, Christie M. Del Castillo
Life of this patent
Estimating the term…
Abstract
This invention relates to bispecific fusion proteins effective in viral neutralization. More specifically, such proteins have two different binding domains, an inducing-binding domain and an induced-binding domain, functionally linked by a peptide linker. Such proteins, nucleic acid molecules encoding them, and their production and use in preventing or treating viral infections are provided. One prototypical bispecific fusion protein is sCD4-SCFv(17b), in which a soluble CD4 fragment (containing domains D1 and D2) is fused to a single chain Fv portion of antibody 17b via a linker.
Claims31
A neutralizing bispecific fusion protein which binds to two sites on a single gp120 molecule, comprising a first binding domain which binds to an inducing site on the gp120, thereby exposing an induced epitope of the gp120;
- a second binding domain which binds to and forms a neutralizing complex with the induced epitope of the same gp120;
- and a linker connecting the first binding domain to the second binding domain, wherein the first binding domain is sCD4, and the second binding domain has an amino acid sequence comprising at least 90% sequence identity to residues 244 through 502 of SEQ ID NO:
- 3.
Dependencies are inferred from the claim text.